Company News

2021-07-21

Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture

Shanghai

Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology Expands existing CDK7 drug di....

2021-04-16

GT Apeiron Therapeutics Strengthens Advisory Board

Shanghai

Keith Lenden and Dr. Honggang Bi has been appointed as new members of the Advisory Board at GT Apeiron Therapeutics, an AI empowered drug discovery start-up developing oncology therapeutics. Mr....

2020-02-01

Apeiron Therapeutics opens US headquarter

San Francisco

Apeiron Therapeutics opens US headquarter in the San Francisco Bay Area. The Bay Area office will enable Apeiron to tap into the deep expertise and talent pool at the intersection of biotechnology and....

2019-06-01

GT Healthcare has launched GT Apeiron, an AI-driven drug development company in Shanghai

Shanghai

GT Healthcare Capital Partners ("GT Healthcare"), a life science-focused private equity partnership which specializes in capital investments and market scalability in Asia/ Greater China region, has l....

2019-06-01

Apeiron announces its partnership with Exscientia

Shanghai

Apeiron Therapeutics is pleased to announce its partnership with Exscientia to accelerate the drug discovery process on several targets in oncology. Details of the deal are not disclosed at this time.....

2019-06-01

Apeiron Therapeutics

Shanghai

Apeiron Therapeutics was launched in 2019 by GT Healthcare Capital Partners. It is a Shanghai-headquartered biotechnology platform utilizing state-of-the-art technologies for drug discovery. About ....